Accelerated Intermittent Theta Burst in Treatment-Naive Adolescents
Part of paid clinical trials in Austin, Texas.
- Sponsor
- University of Texas at Austin
- Study ID
- NCT06523439
- Status
- Recruiting
Conditions
- Depression
- Depression in Adolescence
- Major Depressive Disorder
- Major Depressive Episode
Eligibility Criteria
- Sex
- ALL
- Age
- 14 Years - 19 Years
- Healthy Volunteers
- Not accepted
Interventions
- MagPro X100 edition (MagVenture, Skovlunde, Denmark) — DEVICE10 daily sessions (50 total over 5-days) of SAINT® (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds) guided by MNS, delivered with 50-minute inter-session intervals (10-minute sessions, 50-minutes in between sessions). Stimulation will be delivered at 90% of the resting motor threshold (with depth correction to account for the distance between the scalp and cortex).
- MagPro X100 edition (MagVenture, Skovlunde, Denmark) — DEVICE5 daily sessions (25 total over 5-days) of SAINT® (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds) guided by MNS, delivered with 50-minute inter-session intervals (10-minute sessions, 50-minutes in between sessions). Stimulation will be delivered at 90% of the resting motor threshold (with depth correction to account for the distance between the scalp and cortex).
Study Details
This is a single-site open-label clinical trial of the Stanford Accelerated Intermittent Neuromodulation Therapy (SAINT®) protocol. The goal of this clinical trial is to learn if a new form of transcranial magnetic stimulation (TMS)-known generally as accelerated intermittent theta burst stimulation (aiTBS) and specifically as SAINT®-is effective as a first-line therapy in treating adolescents aged 14-19 years-old in their first episode of depression who have not undergone a full course of depression treatment prior to starting the trial and who remain antidepressant-free throughout the trial. The main questions this trial aims to answer are: * Does SAINT® relieve symptoms of depression as a first-line therapy in adolescents? * Is SAINT® a feasible option as a first-line treatment for adolescent depression? Researchers will measure the depression symptoms in adolescent participants before and after SAINT®. Parents of the adolescent participant will also participate in the study providing information about their experience and preference for TMS as a first-line treatment. Adolescent participants will: * Remain antidepressant-free throughout the study period of 6-7 weeks. * Receive an MRI of their head for precision targeting * Receive 5 days of aiTBS (SAINT®)
Key Dates
- First listed
- Jul 26, 2024
- Start date
- Jan 31, 2025
- Status verified
- Dec 2024
- Primary completion
- Sep 30, 2026
- Completion
- Sep 30, 2026
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Standard SAINT®10 daily sessions (50 total over 5-days) of SAINT® stimulation (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds), delivered with 50-minute inter-session intervals (10-minute sessions, 50-minutes in between sessions). Stimulation will be delivered at 90% of the resting motor threshold (with depth correction to account for the distance between the scalp and cortex).
- Experimental: Truncated SAINT®5 daily sessions (25 total over 5-days) of SAINT® stimulation (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds), delivered with 50-minute inter-session intervals (10-minute sessions, 50-minutes in between sessions). Stimulation will be delivered at 90% of the resting motor threshold (with depth correction to account for the distance between the scalp and cortex).
Primary Outcome Measure
Childhood Depression Rating Scale-Revised (CDRS-R) Remission Rates [ Time Frame: Baseline, One Month Follow Up Visit ]
Central Contacts
- Elyse J Lemke512-495-5566
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Dell Medical School at University of Texas at Austin | Austin | Texas | 78731 | Sean J O'Sullivan, MD, PhD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Austin, TX
Related Studies
- DBS for DepressionRecruiting · Baylor College of Medicine · Dallas, Texas
- Combination of Novel Therapies for CKD Comorbid DepressionPHASE2 · Recruiting · Stony Brook University · Stony Brook, New York
- Youth Depression and Suicide Research NetworkEnrolling By Invitation · University of Texas Southwestern Medical Center · Dallas, Texas
- A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.PHASE3 · Recruiting · AbbVie · Anaheim, California